<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412525</url>
  </required_header>
  <id_info>
    <org_study_id>S63610</org_study_id>
    <nct_id>NCT04412525</nct_id>
  </id_info>
  <brief_title>Comparative Study 27G Vitrectomy vs Larger Gauge Surgery</brief_title>
  <acronym>27G vs larger</acronym>
  <official_title>Comparative Study 27G Vitrectomy vs Larger Gauge Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-arm, mono-center, prospective, interventional comparative case study to compare
      postoperative recovery between the 27G and larger gauge surgical approach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 5, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in post-operative outcome of pain</measure>
    <time_frame>day 1 postoperative</time_frame>
    <description>by assessing the amount of pain on a visual analogue scale (score 0-9)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in post-operative outcome of redness</measure>
    <time_frame>day 1 postoperative</time_frame>
    <description>scoring the amount of redness on a scale 0-4 through eye photos</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in post-operative outcome in grading of anterior chamber cells</measure>
    <time_frame>day 1 postoperative</time_frame>
    <description>clinical assessment by slit lamp examination (Tyndall 0-3 and Cells 0-3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>day 1 postoperative</time_frame>
    <description>best corrected visual acuity in LogMar will be obtained to report the visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-ocular pressure</measure>
    <time_frame>day 1 postoperative</time_frame>
    <description>Millimeter of Mercury pressure (mmHg) will be measured to report the intra-ocular pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain-assessment</measure>
    <time_frame>1 week postoperative</time_frame>
    <description>a questionnaire with visual analogue scale will be used to assess the level of pain up to 1 week after the operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitreoretinal Surgery</condition>
  <arm_group>
    <arm_group_label>27 gauge needle vitrectomy surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>larger than 27 gauge (23G or 25G) needle vitrectomy surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vitrectomy (27G gauge or larger needle)</intervention_name>
    <description>vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.</description>
    <arm_group_label>27 gauge needle vitrectomy surgery</arm_group_label>
    <arm_group_label>larger than 27 gauge (23G or 25G) needle vitrectomy surgery</arm_group_label>
    <other_name>vitrectomy surgery with 27G or larger needle technique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18

          -  No prior vitrectomy surgery in the study eye (for the same eye)

          -  No prior inclusion in this trial

          -  Scheduled for vitrectomy for floater removal or macular surgery (including macular
             holes) without endotamponades such as PFCL, Gas, Silicone oil). (Air tamponade is
             allowed )

        Exclusion Criteria:

          -  â€¢ Patients with serious heart, lung, liver, or kidney dysfunction

               -  Patients with proliferative diabetic retinopathy, endophthalmitis, uveitis, eyes
                  with refraction &gt;+5D or exceeding -8D , or other eye disease that impacts the
                  outcome of vitrectomy surgery

               -  Patients with HIV

               -  Patients with history of drug abuse or alcoholism

               -  Patients participating in other drug or medical device clinical trials before
                  screening for this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ingeborg Vriens</last_name>
    <phone>016342229</phone>
    <phone_ext>016342229</phone_ext>
    <email>ingeborg.vriens@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingeborg Vriens</last_name>
      <phone>003216341819</phone>
      <email>ingeborg.vriens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Stalmans, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

